GIA
PPH icon

Gladstone Institutional Advisory’s VanEck Pharmaceutical ETF PPH Stock Holding History

Gladstone Institutional Advisory’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-40,996
Closed -$3.72M – 685
2024
Q1 		$3.72M Sell
40,996
-5,931
-13% -$519K 0.2% 137
2023
Q4 		$3.82M Buy
+46,927
New +$3.68M 0.21% 124

Other funds holding PPH

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
AT
Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return
MIM
Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCIA
Prime Capital Investment Advisors Overland Park, Kansas $8.65B AUM 19.52% 1-Year Est. Return
FPGK
Financial Partners Group (Kansas) Overland Park, Kansas $836M AUM 21.04% 1-Year Est. Return

Gladstone Institutional Advisory's PPH Position: Q2 2024 in Review

Gladstone Institutional Advisory sold out of VanEck Pharmaceutical ETF (PPH) in Q2 2024, closing a stake of 40,996 shares — an estimated $3.72M sold.

Gladstone Institutional Advisory first reported a position in PPH in Q4 2023 and held it in 2 quarters. The position peaked at $3.82M in Q4 2023. 140 funds tracked by Wall St. Rank hold PPH as of Q2 2024.

  • Gladstone Institutional Advisory reported no remaining VanEck Pharmaceutical ETF position as of Q2 2024 after selling out during the quarter.
  • Gladstone Institutional Advisory sold 40,996 VanEck Pharmaceutical ETF shares in Q2 2024, an estimated $3.72M.
  • Gladstone Institutional Advisory first reported a position in VanEck Pharmaceutical ETF in Q4 2023 and held it in 2 quarters.
  • Gladstone Institutional Advisory's VanEck Pharmaceutical ETF position peaked at $3.82M in Q4 2023.
  • 140 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2024.

Based on Gladstone Institutional Advisory's 13F filing for Q2 2024, filed 2 Aug 2024.